Base de dados : MEDLINE
Pesquisa : C23.550.429 [Categoria DeCS]
Referências encontradas : 3758 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 376 ir para página                         

  1 / 3758 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29091567
[Au] Autor:Rencic J; Zhou M; Hsu G; Dhaliwal G
[Ad] Endereço:From the Department of Medicine, Tufts Medical Center, Boston (J.R., M.Z.); and the Department of Medicine, University of California, San Francisco, and the Medical Service, San Francisco Veterans Affairs Medical Center - both in San Francisco (G.H., G.D.).
[Ti] Título:Circling Back for the Diagnosis.
[So] Source:N Engl J Med;377(18):1778-1784, 2017 Nov 02.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Colecistite Aguda/diagnóstico
Hiperbilirrubinemia/etiologia
Esferocitose Hereditária/diagnóstico
[Mh] Termos MeSH secundário: Dor Abdominal/etiologia
Adulto
Colecistite Aguda/etiologia
Diagnóstico Diferencial
Vesícula Biliar/diagnóstico por imagem
Doença de Gilbert/complicações
Anticorpos Anti-Hepatite B/sangue
Seres Humanos
L-Lactato Desidrogenase/sangue
Masculino
Hepatopatia Gordurosa não Alcoólica/complicações
Obesidade/complicações
Esferocitose Hereditária/complicações
Vômito/etiologia
[Pt] Tipo de publicação:CASE REPORTS; CLINICAL CONFERENCE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hepatitis B Antibodies); EC 1.1.1.27 (L-Lactate Dehydrogenase)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171102
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMcps1701742


  2 / 3758 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28760474
[Au] Autor:Majumder K; Spratt JR; Holley CT; Roy SS; Cogswell RJ; Liao K; John R
[Ad] Endereço:Department of Surgery, University of Minnesota, Minneapolis, Minnesota.
[Ti] Título:Impact of Postoperative Liver Dysfunction on Survival After Left Ventricular Assist Device Implantation.
[So] Source:Ann Thorac Surg;104(5):1556-1562, 2017 Nov.
[Is] ISSN:1552-6259
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Liver dysfunction in left ventricular assist device (LVAD) recipients is common both before and after implantation. Postoperative liver dysfunction (PLD) develops in some LVAD recipients without preoperative liver dysfunction. The aim of this study was to assess clinical outcomes in such patients. METHODS: Records of all patients undergoing implantation of a HeartMate II (HM II, St. Jude Medical, Inc, Minneapolis, MN) LVAD at a single center at the University of Minnesota from January 2005 through June 2014 were analyzed. PLD was defined by hypertransaminasemia or hyperbilirubinemia, or both, during the hospitalization for LVAD implantation. RESULTS: During the study period, 284 patients underwent HM II implantation. Excluded from analysis were 14 recipients with preoperative liver dysfunction. In the final cohort (n = 270), there were no major difference in preoperative characteristics among those patients with versus without PLD. PLD developed in 129 (47.8%) recipients: 16 (12.4%) had isolated hypertransaminasemia (group I), 76 (58.9%) had isolated hyperbilirubinemia (group II), and 37 (28.7%) had combined hypertransaminasemia and hyperbilirubinemia (group III). Group III LVAD recipients had significantly greater rates of 30-day, 90-day, and 1-year mortality, along with significantly higher transfusion requirements and higher rates of renal replacement therapy, prolonged ventilation, and vasopressor use. Moreover, their mortality risk was significantly higher than that of PLD-free LVAD recipients (hazard ratio, 4.6; 95% confidence interval, 2.1 to 10.1; p < 0.001). CONCLUSIONS: Isolated hyperbilirubinemia is common after LVAD implantation. In this study, it was not associated with an increase in early or midterm postoperative mortality. However, postoperative combined transaminasemia and hyperbilirubinemia was associated with a significant increase in early and midterm morbidity and mortality. Further research into the pathogenesis of post-LVAD PLD is necessary.
[Mh] Termos MeSH primário: Causas de Morte
Insuficiência Cardíaca/mortalidade
Insuficiência Cardíaca/cirurgia
Coração Auxiliar/efeitos adversos
Hepatopatias/etiologia
Hepatopatias/mortalidade
[Mh] Termos MeSH secundário: Adulto
Idoso
Análise de Variância
Procedimentos Cirúrgicos Cardíacos/métodos
Procedimentos Cirúrgicos Cardíacos/mortalidade
Estudos de Coortes
Bases de Dados Factuais
Feminino
Mortalidade Hospitalar
Seres Humanos
Hiperbilirrubinemia/etiologia
Hiperbilirrubinemia/fisiopatologia
Estimativa de Kaplan-Meier
Hepatopatias/patologia
Modelos Logísticos
Masculino
Meia-Idade
Análise Multivariada
Complicações Pós-Operatórias/mortalidade
Complicações Pós-Operatórias/fisiopatologia
Prognóstico
Modelos de Riscos Proporcionais
Estudos Retrospectivos
Medição de Risco
Análise de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171115
[Lr] Data última revisão:
171115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170802
[St] Status:MEDLINE


  3 / 3758 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28681433
[Au] Autor:Zonneveld R; Lamers M; Schonewille H; Brand A; Kanhai HHH; Zijlmans WCWR
[Ad] Endereço:Scientific Research Center Suriname, Paramaribo, Suriname.
[Ti] Título:Prevalence of positive direct antiglobulin test and clinical outcomes in Surinamese newborns from D-negative women.
[So] Source:Transfusion;57(10):2496-2501, 2017 Oct.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In low-resource countries, screening for D antibodies to detect pregnancies at risk for hemolytic disease of the newborn is not routine practice. Retrospective data showed that 5.5% of Surinamese newborns of D-negative women had a positive direct antiglobulin test (DAT), indicating the presence of maternal antibodies against fetal antigens. Here, the frequency and clinical relevance of DAT positivity is evaluated. STUDY DESIGN AND METHODS: Between April 2015 and June 2016, an observational, multicenter cohort study was undertaken among Surinamese newborns born to D-negative women. In newborns, the DAT was performed, and clinical outcomes between DAT-negative and DAT-positive newborns were compared. RESULTS: Of the 232 evaluable newborns, 19 (8.2%) had a positive DAT, of which 11 of 15 antibody-tested newborns had D antibodies. DAT-positive newborns had lower hemoglobin levels (p = 0.02) and a trend toward higher bilirubin concentrations (p = 0.09) in the first days of life compared with DAT-negative newborns. DAT-positive newborns were admitted more frequently (p = 0.02), needed phototherapy treatment almost four times as often as DAT-negative newborns (26% vs. 7%; p = 0.008), and therapy took 2 days longer (p = 0.01). Exchange transfusions were performed in two newborns with D antibodies, both complicated with sepsis. The hospital stay was 2.5 days longer for DAT-positive newborns (p = 0.007). Overall, the prevalence of hemolytic disease of the newborn requiring treatment was 2.2% among the whole cohort of newborns. CONCLUSION: We found a high prevalence of DAT positivity with substantial need for hyperbilirubinemia treatment in newborns in Suriname. These results stress the necessity for better management procedures in D-negative women.
[Mh] Termos MeSH primário: Teste de Coombs/estatística & dados numéricos
Eritroblastose Fetal/etiologia
Sistema do Grupo Sanguíneo Rh-Hr/sangue
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Hiperbilirrubinemia
Recém-Nascido
Gravidez
Prevalência
Estudos Retrospectivos
Imunoglobulina rho(D)/sangue
Suriname
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (RHO(D) antibody); 0 (Rh-Hr Blood-Group System); 0 (Rho(D) Immune Globulin); 0 (Rho(D) antigen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170707
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14229


  4 / 3758 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28669611
[Au] Autor:Watchko JF; Spitzer AR; Clark RH
[Ad] Endereço:Division of Newborn Medicine, Department of Pediatrics, University of Pittsburgh School of Medicine, Magee-Women's Research Institute, Pittsburgh, PA.
[Ti] Título:Prevalence of Hypoalbuminemia and Elevated Bilirubin/Albumin Ratios in a Large Cohort of Infants in the Neonatal Intensive Care Unit.
[So] Source:J Pediatr;188:280-286.e4, 2017 Sep.
[Is] ISSN:1097-6833
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To provide descriptive data on serum albumin levels and the bilirubin to albumin (B/A) ratio in neonates admitted to the neonatal intensive care unit, assess the effect of gestational and chronological age on serum albumin and the B/A ratio, and evaluate the association between extreme values and mortality. STUDY DESIGN: Using a retrospective cohort design, we queried the Pediatrix clinical data warehouse for all infants born between 23 and 41 weeks of gestation from 1997 to 2014 who had a report of both a serum albumin and total serum bilirubin (TSB) level on the same day between birth and 14 days of life. RESULTS: There were 382 190 paired albumin and bilirubin levels across 164 401 neonates (15% of the 1 072 682 infants in the clinical data warehouse). Both gestational age and postnatal age were independent factors that influenced the values for serum albumin, TSB, and B/A ratio (ANOVA; P < .0001). TSB and B/A ratios values above birth weight-specific thresholds for exchange transfusions were uncommon (<6% of infants). Hypoalbuminemia (<2.5 mg/dL) was common (29% of infants). Neonates with serum albumin levels <2.5 g/dL or with B/A ratio levels exceeding exchange thresholds were at higher risk of death compared with infants who did not exceed these levels. This association was independent of other risk factors (estimated gestational age, birth weight, sex, and the presence of a major anomaly). CONCLUSION: Both gestational age and postnatal age influence TSB, albumin, and B/A ratios; hypoalbuminemia and extreme B/A ratios are associated with an increased risk of death.
[Mh] Termos MeSH primário: Hiperbilirrubinemia/epidemiologia
Hipoalbuminemia/epidemiologia
Unidades de Terapia Intensiva Neonatal
Albumina Sérica/análise
[Mh] Termos MeSH secundário: Fatores Etários
Índice de Apgar
Peso ao Nascer
Estudos de Coortes
Feminino
Idade Gestacional
Mortalidade Hospitalar
Seres Humanos
Recém-Nascido
Masculino
Prevalência
Respiração Artificial/estatística & dados numéricos
Estudos Retrospectivos
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Serum Albumin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170704
[St] Status:MEDLINE


  5 / 3758 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28662083
[Au] Autor:Yu C; Li H; Zhang Q; He H; Chen X; Hua Z
[Ad] Endereço:Department of Neonatology, Children's Hospital of Chongqing Medical University, Chongqing, China.
[Ti] Título:Report about term infants with severe hyperbilirubinemia undergoing exchange transfusion in Southwestern China during an 11-year period, from 2001 to 2011.
[So] Source:PLoS One;12(6):e0179550, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: This study was intended to explore the etiology and risk factors of severe neonatal hyperbilirubinemia and to analyze the adverse events associated with ECT (Exchange Transfusion), as well as to identify the factors related to the poor prognosis. METHODS: All of the full-term neonates who had undergone ECT for hyperbilirubinemia at Children's Hospital of Chongqing Medical University from January 2001 to December 2011 were enrolled in this study. General demographic characteristics, comorbidities, pre- and post-exchange TSB(Total Serum Bilirubin) levels, duration and frequency of ECT, and clinical outcomes were recorded and analyzed anonymously. RESULTS: Of 614 total infants, 368 patients (59.9%) with ABO incompatibility were identified, of whom 197 (53.5%) developed acute bilirubin encephalopathy (ABE) and 16 (4.3%) suffered a poor prognosis. The etiology was unidentified in 103 patients (16.8%), of whom 62 (60.1%) developed ABE and 9 (8.7%) had a poor prognosis. Identified adverse events secondary to ECT included thrombocytopenia (54.6%), hyperglycemia (42.8%), apnea (3.3%) and necrotizing enterocolitis (NEC) (1.3%). No ECT-related mortality was documented in this study. CONCLUSIONS: The etiology, peak TSB level before ECT, and time of ECT had a significant impact on the outcome of severe neonatal hyperbilirubinemia. ABO incompatibility was the most common cause of extreme neonatal hyperbilirubinemia. Pathological weight loss could be involved in the development of extreme hyperbilirubinemia with an unidentified cause.
[Mh] Termos MeSH primário: Transfusão de Sangue
Hiperbilirrubinemia/terapia
[Mh] Termos MeSH secundário: China
Feminino
Seres Humanos
Recém-Nascido
Masculino
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170630
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0179550


  6 / 3758 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28640024
[Au] Autor:Gerth HU; Pohlen M; Thölking G; Pavenstädt H; Brand M; Hüsing-Kabar A; Wilms C; Maschmeier M; Kabar I; Torner J; Pavesi M; Arroyo V; Banares R; Schmidt HHJ
[Ad] Endereço:1Department of Medicine D, Division of General Internal Medicine, Nephrology, and Rheumatology, University Hospital Muenster, Muenster, Germany. 2Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany. 3Department of Transplant Medicine, University Hospital Muenster, Muenster, Germany. 4Data Management Center of the EASL-CLIF Consortium, CIBEReHD, Barcelona, Spain. 5Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain. 6Liver Unit, Hospital General Universitario Gregorio Maranon, IiSGM, Madrid, Spain.
[Ti] Título:Molecular Adsorbent Recirculating System Can Reduce Short-Term Mortality Among Patients With Acute-on-Chronic Liver Failure-A Retrospective Analysis.
[So] Source:Crit Care Med;45(10):1616-1624, 2017 Oct.
[Is] ISSN:1530-0293
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Acute-on-chronic liver failure is associated with numerous consecutive organ failures and a high short-term mortality rate. Molecular adsorbent recirculating system therapy has demonstrated beneficial effects on the distinct symptoms, but the associated mortality data remain controversial. DESIGN: Retrospective analysis of acute-on-chronic liver failure patients receiving either standard medical treatment or standard medical treatment and molecular adsorbent recirculating system. Secondary analysis of data from the prospective randomized Recompensation of Exacerbated Liver Insufficiency with Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure trial by applying the recently introduced Chronic Liver Failure-criteria. SETTING: Medical Departments of University Hospital Muenster (Germany). PATIENTS: This analysis was conducted in two parts. First, 101 patients with acute-on-chronic liver failure grades 1-3 and Chronic Liver Failure-C-Organ Failure liver subscore equals to 3 but stable pulmonary function were identified and received either standard medical treatment (standard medical treatment, n = 54) or standard medical treatment and molecular adsorbent recirculating system (n = 47) at the University Hospital Muenster. Second, the results of this retrospective analysis were tested against the Recompensation of Exacerbated Liver Insufficiency with Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure trial. INTERVENTIONS: Standard medical treatment and molecular adsorbent recirculating system. MEASUREMENTS AND MAIN RESULTS: Additionally to improved laboratory variables (bilirubin and creatinine), the short-term mortality (up to day 14) of the molecular adsorbent recirculating system group was significantly reduced compared with standard medical treatment. A reduced 14-day mortality rate was observed in the molecular adsorbent recirculating system group (9.5% vs 50.0% with standard medical treatment; p = 0.004), especially in patients with multiple organ failure (acute-on-chronic liver failure grade 2-3). Concerning the affected organ system, this effect of molecular adsorbent recirculating system on mortality was particularly evident among patients with increased kidney, brain, or coagulation Chronic Liver Failure-C-Organ Failure subscores. Subsequent reanalysis of the Recompensation of Exacerbated Liver Insufficiency with Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure dataset with adoption of the Chronic Liver Failure-classification resulted in similar findings. CONCLUSIONS: Molecular adsorbent recirculating system treatment was associated with an improved short-term survival of patients with acute-on-chronic liver failure and multiple organ failure. Among these high-risk patients, molecular adsorbent recirculating system treatment might bridge to liver recovery or liver transplantation.
[Mh] Termos MeSH primário: Insuficiência Hepática Crônica Agudizada/mortalidade
Insuficiência Hepática Crônica Agudizada/terapia
Desintoxicação por Sorção
[Mh] Termos MeSH secundário: Insuficiência Hepática Crônica Agudizada/classificação
Bilirrubina/análise
Creatinina/análise
Feminino
Seres Humanos
Hiperbilirrubinemia/terapia
Masculino
Meia-Idade
Escores de Disfunção Orgânica
Ensaios Clínicos Controlados Aleatórios como Assunto
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
AYI8EX34EU (Creatinine); RFM9X3LJ49 (Bilirubin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170623
[St] Status:MEDLINE
[do] DOI:10.1097/CCM.0000000000002562


  7 / 3758 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28503958
[Au] Autor:Ree IMC; Smits-Wintjens VEHJ; van der Bom JG; van Klink JMM; Oepkes D; Lopriore E
[Ad] Endereço:a Department of Pediatrics , Leiden University Medical Center , Leiden , The Netherlands.
[Ti] Título:Neonatal management and outcome in alloimmune hemolytic disease.
[So] Source:Expert Rev Hematol;10(7):607-616, 2017 Jul.
[Is] ISSN:1747-4094
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Hemolytic disease of the fetus and newborn (HDFN) occurs when fetal and neonatal erythroid cells are destroyed by maternal erythrocyte alloantibodies, it leads to anemia and hydrops in the fetus, and hyperbilirubinemia and kernicterus in the newborn. Postnatal care consists of intensive phototherapy and exchange transfusions to treat severe hyperbilirubinemia and top-up transfusions to treat early and late anemia. Other postnatal complications have been reported such as thrombocytopenia, iron overload and cholestasis requiring specific management. Areas covered: This review focusses on the current neonatal management and outcome of hemolytic disease and discusses postnatal treatment options as well as literature on long-term neurodevelopmental outcome. Expert commentary: Despite major advances in neonatal management, multiple issues have to be addressed to optimize postnatal management and completely eradicate kernicterus. Except for strict adherence to guidelines, improvement could be achieved by clarifying the epidemiology and pathophysiology of HDFN. Several pharmacotherapeutic agents should be further researched as alternative treatment options in hyperbilirubinemia, including immunoglobulins, albumin, phenobarbital, metalloporphyrins, zinc, clofibrate and prebiotics. Larger trials are warranted to evaluate EPO, folate and vitamin E in neonates. Long-term follow-up studies are needed in HDFN, especially on thrombocytopenia, iron overload and cholestasis.
[Mh] Termos MeSH primário: Anemia Hemolítica/imunologia
Anemia Hemolítica/terapia
Anemia Neonatal/imunologia
Anemia Neonatal/terapia
Isoanticorpos/imunologia
[Mh] Termos MeSH secundário: Anemia Hemolítica/complicações
Anemia Hemolítica/diagnóstico
Anemia Neonatal/complicações
Anemia Neonatal/diagnóstico
Terapia Combinada
Gerenciamento Clínico
Transfusão Total
Hidratação/métodos
Seres Humanos
Hiperbilirrubinemia/diagnóstico
Hiperbilirrubinemia/etiologia
Hiperbilirrubinemia/terapia
Imunoglobulinas Intravenosas
Recém-Nascido
Kernicterus/diagnóstico
Kernicterus/etiologia
Kernicterus/terapia
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Immunoglobulins, Intravenous); 0 (Isoantibodies)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171009
[Lr] Data última revisão:
171009
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170516
[St] Status:MEDLINE
[do] DOI:10.1080/17474086.2017.1331124


  8 / 3758 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28415925
[Au] Autor:Parker W; Hornik CD; Bilbo S; Holzknecht ZE; Gentry L; Rao R; Lin SS; Herbert MR; Nevison CD
[Ad] Endereço:1 Departments of Surgery, Duke University Medical Center, Durham, NC USA.
[Ti] Título:The role of oxidative stress, inflammation and acetaminophen exposure from birth to early childhood in the induction of autism.
[So] Source:J Int Med Res;45(2):407-438, 2017 Apr.
[Is] ISSN:1473-2300
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The wide range of factors associated with the induction of autism is invariably linked with either inflammation or oxidative stress, and sometimes both. The use of acetaminophen in babies and young children may be much more strongly associated with autism than its use during pregnancy, perhaps because of well-known deficiencies in the metabolic breakdown of pharmaceuticals during early development. Thus, one explanation for the increased prevalence of autism is that increased exposure to acetaminophen, exacerbated by inflammation and oxidative stress, is neurotoxic in babies and small children. This view mandates extreme urgency in probing the long-term effects of acetaminophen use in babies and the possibility that many cases of infantile autism may actually be induced by acetaminophen exposure shortly after birth.
[Mh] Termos MeSH primário: Acetaminofen/efeitos adversos
Analgésicos não Entorpecentes/efeitos adversos
Transtorno Autístico/etiologia
Transtorno Autístico/fisiopatologia
Estresse Oxidativo
[Mh] Termos MeSH secundário: Aspartame/administração & dosagem
Aspartame/metabolismo
Aspartame/toxicidade
Transtorno Autístico/diagnóstico
Criança
Pré-Escolar
Feminino
Ácido Fólico/efeitos adversos
Seres Humanos
Hiperbilirrubinemia/complicações
Hiperbilirrubinemia/fisiopatologia
Lactente
Inflamação
Masculino
Metais Pesados/toxicidade
Organofosfatos/toxicidade
Gravidez
Fatores de Risco
Timerosal/toxicidade
Vitamina B 12/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Analgesics, Non-Narcotic); 0 (Metals, Heavy); 0 (Organophosphates); 2225PI3MOV (Thimerosal); 362O9ITL9D (Acetaminophen); 935E97BOY8 (Folic Acid); P6YC3EG204 (Vitamin B 12); Z0H242BBR1 (Aspartame)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170419
[St] Status:MEDLINE
[do] DOI:10.1177/0300060517693423


  9 / 3758 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28398539
[Au] Autor:Foshat M; Ruff HM; Fischer WG; Beach RE; Fowler MR; Ju H; Aronson JF; Afrouzian M
[Ad] Endereço:Department of Pathology.
[Ti] Título:Bile Cast Nephropathy in Cirrhotic Patients: Effects of Chronic Hyperbilirubinemia.
[So] Source:Am J Clin Pathol;147(5):525-535, 2017 May 01.
[Is] ISSN:1943-7722
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: The aim of this study was to determine the prevalence of bile cast nephropathy (BCN) in autopsied cirrhotic patients and to correlate BCN with clinical and laboratory data to direct attention to this underrecognized renal complication of liver failure. Methods: We assessed 114 autopsy cases of cirrhosis for the presence of renal intratubular bile casts using Hall stain for bile. Presence of bile casts was correlated with etiology of cirrhosis, clinical and laboratory data, and histologic findings. Results: Bile casts were identified in 55% of cases. The most common etiology of cirrhosis was hepatitis C virus (HCV) infection (52%), and serum creatinine ( P = .02) and serum urea nitrogen ( P = .01) were significantly higher in the Hall-positive group. Conjugated bilirubin was below 20 mg/dL in 90%, and levels below 10 mg/dL were noted in 80% of cases. Conclusions: To our knowledge, this is the largest study of BCN in human subjects and a first report describing the association of BCN with HCV-related cirrhosis. We demonstrated that in the face of protracted chronic hyperbilirubinemia, bile casts are formed at much lower bilirubin levels than previously thought. Furthermore, we proposed an algorithm to assist in better identification of bile casts.
[Mh] Termos MeSH primário: Hiperbilirrubinemia/complicações
Nefropatias/epidemiologia
Nefropatias/etiologia
Cirrose Hepática/complicações
[Mh] Termos MeSH secundário: Adulto
Idoso
Autopsia
Bile
Feminino
Seres Humanos
Masculino
Meia-Idade
Prevalência
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.1093/ajcp/aqx030


  10 / 3758 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28366015
[Au] Autor:Jones DF; McRea AR; Knowles JD; Lin FC; Burnette E; Reller LA; Lohr JA
[Ad] Endereço:1 North Carolina Children's Hospital, Chapel Hill, NC, USA.
[Ti] Título:A Prospective Comparison of Transcutaneous and Serum Bilirubin Within Brief Time Intervals.
[So] Source:Clin Pediatr (Phila);56(11):1013-1017, 2017 Oct.
[Is] ISSN:1938-2707
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The American Academy of Pediatrics recommends screening newborns ≥35 weeks' gestation with total serum bilirubin (TSB) or transcutaneous bilirubin (TcB) to detect hyperbilirubinemia. Retrospective studies show TcB measurements strongly correlate with TSB; however, few prospective trials document this relationship. Furthermore, Dräger's newest TcB instrument, JM-105, remains unstudied in the United States. We measure TcB on foreheads and sternums of newborns using JM-105 and Bilichek devices within 30 minutes of TSB measurement. We find best overall TcB/TSB correlation with JM-105 on the sternum (mean TcB-TSB difference: -0.21 ± 1.15 mg/dL). Correlations between paired measurements for TcB on the sternum using JM-105 were 0.93 for all TSB levels (n = 178), 0.82 for TSB > 10 (n = 19), 0.69 for TSB > 12 (n = 11), and 0.52 for TSB > 15 (n = 6). TcB accuracy via JM-105 on the sternum significantly differed among races ( P < .001). For 5% of paired measurements, TcB with JM-105 on the sternum underestimated TSB by ≥2 mg/dL, and for <1% by ≥3 mg/dL.
[Mh] Termos MeSH primário: Bilirrubina/análise
Hiperbilirrubinemia/diagnóstico
Triagem Neonatal/instrumentação
Triagem Neonatal/métodos
[Mh] Termos MeSH secundário: Bilirrubina/sangue
Feminino
Seres Humanos
Hiperbilirrubinemia/sangue
Recém-Nascido
Masculino
Estudos Prospectivos
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
RFM9X3LJ49 (Bilirubin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170913
[Lr] Data última revisão:
170913
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE
[do] DOI:10.1177/0009922817701170



página 1 de 376 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde